Open AccessCan the Use of Continuous Glucose Monitoring Improve Glycemic Control in Patients with Type 1 and 2 Diabetes Receiving Dialysis?
Author(s) -
Tobias Bomholt,
Dea Haagensen Kofod,
Kirsten Nørgaard,
Peter Rossing,
Bo FeldtRasmussen,
Mads Hornum
Publication year - 2022
Publication title -
the nephron journals/nephron journals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.951
H-Index - 72
eISSN - 2235-3186
pISSN - 1660-8151
DOI - 10.1159/000525676
Subject(s) - medicine , glycemic , hypoglycemia , dialysis , population , type 2 diabetes , continuous glucose monitoring , type 1 diabetes , diabetes mellitus , intensive care medicine , endocrinology , environmental health
Hemoglobin A1c (HbA1c) is an unreliable glycemic marker in the dialysis population, and alternative methods of glycemic monitoring should be considered. Continuous glucose monitoring (CGM) measures interstitial glucose, an indirect measure of plasma glucose, and allows for estimating mean sensor glucose, glucose variability, and time in ranges. Thus, CGM provides a more nuanced picture of glycemic variables than HbA1c, which only informs about average glucose and not variation in glucose or hypoglycemia.